Literature DB >> 16217720

[Quality of life assessment in Inflammatory Bowel Disease (IBD): German version of the Inflammatory Bowel Disease Questionnaire (IBDQ-D; disease-specific instrument for quality of life assessment) -- first application and comparison with international investigations].

K-H Janke1, U Steder-Neukamm, M Bauer, A Raible, C Meisner, J C Hoffmann, M Gregor, B Klump, W Häuser.   

Abstract

BACKGROUND: Health-related quality of life (HRQOL) is an important outcome-parameter in health research and care. The aim of the working group Quality of Life in the Competence Network Inflammatory Bowel Disease (IBD; in the original German: "Kompetenznetz chronisch entzündliche Darmerkrankungen") is to generate instruments for assessment of HRQOL and its implementation as standards in clinical trials, health care and research in IBD.
METHODS: The Inflammatory Bowel Disease Questionnaire (IBDQ) is an international validated disease specific instrument for HRQOL-assessment. A German version of the IBDQ was elaborated and tested in 415 outpatients with Crohn's disease (CD, n = 306) and ulcerative colitis (UC, n = 109). The aim of the study was to compare the results of HRQOL-assessment (IBDQ-D) with international investigations, to correlate HRQOL results with disease activity and to preform a pretest of psychometric properties.
RESULTS: International data suggest that the IBDQ-D is a suitable instrument for HRQOL-assessment in CD and UC. For both disease a statistically significant negative correlation with disease activity was found. Tested psychometric properties do not suggest that a revision of the IBDQ-D is required. The IBDQ-D offers the HRQOL-assessment as an primary or secondary outcome in clinical trials in IBD in Germany.

Entities:  

Mesh:

Year:  2005        PMID: 16217720     DOI: 10.1055/s-2005-858579

Source DB:  PubMed          Journal:  Gesundheitswesen        ISSN: 0941-3790


  4 in total

1.  The ABACHAI clinical trial protocol: Safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: A non controlled phase 2 clinical trial.

Authors:  Máté Krausz; Annette Uhlmann; Ina Caroline Rump; Gabriele Ihorst; Sigune Goldacker; Georgios Sogkas; Sara Posadas-Cantera; Reinhold Schmidt; Manuel Feißt; Laia Alsina; Ingunn Dybedal; Mike Recher; Klaus Warnatz; Bodo Grimbacher
Journal:  Contemp Clin Trials Commun       Date:  2022-09-24

2.  Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results.

Authors:  Niels Teich; Harald Grümmer; Eric Jörgensen; Thomas Liceni; Frank Holtkamp-Endemann; Tim Fischer; Susanne Hohenberger
Journal:  World J Gastroenterol       Date:  2020-06-07       Impact factor: 5.742

3.  Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management.

Authors:  Martina Ledergerber; Brian M Lang; Henriette Heinrich; Luc Biedermann; Stefan Begré; Jonas Zeitz; Niklas Krupka; Andreas Rickenbacher; Matthias Turina; Thomas Greuter; Philipp Schreiner; René Roth; Alexander Siebenhüner; Stephan R Vavricka; Gerhard Rogler; Niko Beerenwinkel; Benjamin Misselwitz
Journal:  BMC Gastroenterol       Date:  2021-02-05       Impact factor: 3.067

4.  Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months.

Authors:  Niels Teich; Harald Grümmer; Eric Jörgensen; Thomas Liceni; Frank Holtkamp-Endemann; Tim Fischer; Susanne Hohenberger
Journal:  BMC Gastroenterol       Date:  2021-04-12       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.